loading

Warum fällt Aclaris Therapeutics Inc-Aktie (ACRS)?

2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
diagnostics_research LH
$242.17
price down icon 0.84%
$172.39
price up icon 3.11%
$141.68
price up icon 0.18%
diagnostics_research WAT
$411.17
price down icon 0.56%
diagnostics_research MTD
$1,326.80
price up icon 0.34%
$433.68
price up icon 1.61%
Kapitalisierung:     |  Volumen (24h):